Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis
Journal of Clinical Oncology, 08/10/09
Tefferi A et al. – Pomalidomide therapy at 0.5 or 2 mg/d with or without an abbreviated course of prednisone is well tolerated in patients with myelofibrosis and active in the treatment of anemia.
Related Articles
Iron-Refractory Iron Deficiency Anemia
Seminars in Hematology, 10/05/09
Relevance Score: 94%
Fanconi Anemia Complementation Group FANCD2 Protein Serine 331 Phosphorylation Is Important for Fanconi Anemia Pathway Function and BRCA2 Interaction
Cancer Research, 11/17/09
Relevance Score: 91%
A guide to diagnosis of iron deficiency and iron deficiency anemia in digestive diseases
World Journal of Gastroenterology, 10/14/09
Relevance Score: 91%
Prevalence and pathogenesis of anemia in Inflammatory Bowel disease. Influence of anti-tumor necrosis factor-alpha treatment
Haematologica, 10/12/09
Relevance Score: 91%
Hereditary Sideroblastic Anemias: Pathophysiology, Diagnosis, and Treatment
Seminars in Hematology, 10/05/09
Relevance Score: 91%
Today in Anemia/Polycythemia...keeping you current
Receive free subspecialty "5-minute updates" via email
Peripheral arterial tonometry in assessing endothelial dysfunction in pediatric sickle cell disease
Pediatric Hematology and Oncology, 11/25/09
Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature
Pediatric Hematology and Oncology, 11/25/09
Src tyrosine kinase pre-activation is associated with platelet hypersensitivity in essential thrombocythemia and polycythemia vera
Blood, 11/25/09
Today in Myeloproliferative Dz...keeping you current
Receive free subspecialty "5-minute updates" via email
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
Oncogene, 11/25/09
International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis
Blood, 11/25/09
Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation
Experimental Hematology, 11/25/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
Oncogene, 11/25/09
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
Investigational New Drugs, 11/25/09
Adding more content to screening: reactivation of FOXO as a therapeutic strategy
Clinical and Translational Oncology, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


